CG Oncology Statistics

Total Valuation

CG Oncology has a market cap or net worth of $5.53 billion. The enterprise value is $4.80 billion.

Market Cap	5.53B
Enterprise Value	4.80B

Important Dates

The next estimated earnings date is Friday, May 8, 2026, before market open.

Earnings Date	May 8, 2026
Ex-Dividend Date	n/a

Share Statistics

CG Oncology has 84.44 million shares outstanding. The number of shares has increased by 23.69% in one year.

Current Share Class	84.44M
Shares Outstanding	84.44M
Shares Change (YoY)	+23.69%
Shares Change (QoQ)	+4.35%
Owned by Insiders (%)	0.97%
Owned by Institutions (%)	92.76%
Float	69.04M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1,369.67
Forward PS	378.42
PB Ratio	7.03
P/TBV Ratio	7.46
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	1,187.70
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 24.63, with a Debt / Equity ratio of 0.01.

Current Ratio	24.63
Quick Ratio	24.09
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -21.67% and return on invested capital (ROIC) is -15.97%.

Return on Equity (ROE)	-21.67%
Return on Assets (ROA)	-15.42%
Return on Invested Capital (ROIC)	-15.97%
Return on Capital Employed (ROCE)	-25.08%
Weighted Average Cost of Capital (WACC)	8.11%
Revenue Per Employee	$28,451
Profits Per Employee	-$1.13M
Employee Count	142
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +193.03% in the last 52 weeks. The beta is 0.70, so CG Oncology's price volatility has been lower than the market average.

Beta (5Y)	0.70
52-Week Price Change	+193.03%
50-Day Moving Average	64.39
200-Day Moving Average	45.27
Relative Strength Index (RSI)	46.02
Average Volume (20 Days)	1,173,080

Short Selling Information

The latest short interest is 9.53 million, so 11.29% of the outstanding shares have been sold short.

Short Interest	9.53M
Short Previous Month	10.54M
Short % of Shares Out	11.29%
Short % of Float	13.81%
Short Ratio (days to cover)	6.69

Income Statement

In the last 12 months, CG Oncology had revenue of $4.04 million and -$161.00 million in losses. Loss per share was -$2.08.

Revenue	4.04M
Gross Profit	-117.25M
Operating Income	-190.77M
Pretax Income	-161.00M
Net Income	-161.00M
EBITDA	-189.33M
EBIT	-190.77M
Loss Per Share	-$2.08

Full Income Statement

Balance Sheet

The company has $742.16 million in cash and $7.02 million in debt, giving a net cash position of $735.13 million or $8.71 per share.

Cash & Cash Equivalents	742.16M
Total Debt	7.02M
Net Cash	735.13M
Net Cash Per Share	$8.71
Equity (Book Value)	752.60M
Book Value Per Share	9.33
Working Capital	728.64M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$132.35 million and capital expenditures -$134,000, giving a free cash flow of -$132.48 million.

Operating Cash Flow	-132.35M
Capital Expenditures	-134,000
Depreciation & Amortization	1.45M
Net Borrowing	n/a
Free Cash Flow	-132.48M
FCF Per Share	-$1.57

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-4,722.13%
Pretax Margin	-3,985.02%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

CG Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-23.69%
Shareholder Yield	-23.69%
Earnings Yield	-2.91%
FCF Yield	-2.39%

Analyst Forecast

The average price target for CG Oncology is $77.64, which is 18.44% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$77.64
Price Target Difference	18.44%
Analyst Consensus	Strong Buy
Analyst Count	11
Revenue Growth Forecast (5Y)	126.45%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

CG Oncology has an Altman Z-Score of 36.09 and a Piotroski F-Score of 3.

Altman Z-Score	36.09
Piotroski F-Score	3